Syntara Limited has released a press release.
Preliminary Final Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Syntara
- Guidance from FDA on amsulostat clinical progression
- Reinstatement to Quotation
- Suspension from Quotation
- Quarterly Appendix 4C Cash Flow Report
- Quarterly Shareholder Report
Later from Syntara
- Positive top-line Phase 2a data confirms competitive profile
- Quarterly Shareholder Report and Appendix 4C
- Skin scarring program to progress on positive Phase1a result
- SNT-4728 Phase 2 iRBD Parkinsons UK Trial fully recruited
- Amsulostat and Garvan in MRFF funded pancreatic trial
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara